Rebranding Invizyne to eXoZymes Signifies a Sustainable Paradigm Shift in Chemical Production Leveraging AI-Engineered Enzymes
Invizyne Technologies announced its corporate rebranding to eXoZymes Inc, with its stock trading symbol changing from IZTC to EXOZ on the Nasdaq Capital Market. The company introduces 'exozymes' as a new scientific concept, positioning it as the successor to synthetic biology (SynBio), particularly focusing on industrial-scale production.
eXoZymes specializes in AI-engineered enzymes designed to operate outside living cells in bioreactors, transforming feedstocks into valuable chemicals, medicines, and biofuels. The company emphasizes this technology's potential to replace traditional chemical production methods with sustainable alternatives. The development process, powered by AI and enzymes, significantly reduces production timelines, with the company expecting to announce a new chemical development completed in just weeks.
Invizyne Technologies ha annunciato il suo rebranding aziendale a eXoZymes Inc, con il simbolo di borsa che cambia da IZTC a EXOZ sul Nasdaq Capital Market. L'azienda introduce il concetto scientifico di 'exozymes', posizionandolo come il successore della biologia sintetica (SynBio), con un focus particolare sulla produzione su scala industriale.
eXoZymes si specializza in enzimi ingegnerizzati con AI progettati per operare al di fuori delle cellule viventi in bioreattori, trasformando materie prime in sostanze chimiche preziose, medicinali e biocarburanti. L'azienda sottolinea il potenziale di questa tecnologia di sostituire i metodi tradizionali di produzione chimica con alternative sostenibili. Il processo di sviluppo, alimentato da AI e enzimi, riduce significativamente i tempi di produzione, con l'azienda che prevede di annunciare un nuovo sviluppo chimico completato in sole settimane.
Invizyne Technologies anunció su rebranding corporativo a eXoZymes Inc, con su símbolo de cotización cambiando de IZTC a EXOZ en el Nasdaq Capital Market. La compañía presenta 'exozymes' como un nuevo concepto científico, posicionándolo como el sucesor de la biología sintética (SynBio), enfocándose particularmente en la producción a escala industrial.
eXoZymes se especializa en enzimas diseñadas con IA que operan fuera de las células vivas en biorreactores, transformando materias primas en productos químicos valiosos, medicamentos y biocombustibles. La empresa enfatiza el potencial de esta tecnología para reemplazar los métodos de producción química tradicionales con alternativas sostenibles. El proceso de desarrollo, impulsado por IA y enzimas, reduce significativamente los plazos de producción, y la compañía espera anunciar un nuevo desarrollo químico completado en solo unas semanas.
Invizyne Technologies는 기업 리브랜딩을 eXoZymes Inc로 발표하며, 주식 거래 기호가 IZTC에서 EXOZ로 변경되었다고 전했습니다. 이 회사는 'exozymes'라는 새로운 과학 개념을 도입하며, 이를 합성 생물학(SynBio)의 후계자로 자리매김하고, 특히 산업 규모의 생산에 중점을 두고 있습니다.
eXoZymes는 AI 엔지니어링 효소를 전문으로 하며, 이 효소는 생명 세포 외부에서 바이오리액터에서 작동하여 원료를 가치 있는 화학 물질, 의약품 및 바이오연료로 변환합니다. 이 회사는 이 기술이 전통적인 화학 생산 방법을 지속 가능한 대안으로 대체할 수 있는 잠재력을 강조합니다. AI와 효소에 의해 추진되는 개발 과정은 생산 기간을 획기적으로 단축시키며, 회사는 몇 주 만에 완료된 새로운 화학 개발을 발표할 것으로 예상하고 있습니다.
Invizyne Technologies a annoncé son rebranding d'entreprise à eXoZymes Inc, avec son symbole boursier passant de IZTC à EXOZ sur le Nasdaq Capital Market. L'entreprise introduit 'exozymes' comme un nouveau concept scientifique, le positionnant comme le successeur de la biologie synthétique (SynBio), en se concentrant particulièrement sur la production à l'échelle industrielle.
eXoZymes se spécialise dans les enzymes conçues par IA qui fonctionnent en dehors des cellules vivantes dans des bioréacteurs, transformant des matières premières en produits chimiques précieux, médicaments et biocarburants. L'entreprise met en avant le potentiel de cette technologie pour remplacer les méthodes de production chimique traditionnelles par des alternatives durables. Le processus de développement, alimenté par l'IA et les enzymes, réduit considérablement les délais de production, l'entreprise s'attendant à annoncer un nouveau développement chimique achevé en seulement quelques semaines.
Invizyne Technologies hat sein Corporate Rebranding zu eXoZymes Inc bekannt gegeben, wobei das Börsensymbol von IZTC auf EXOZ an der Nasdaq Capital Market geändert wird. Das Unternehmen führt 'exozymes' als neues wissenschaftliches Konzept ein und positioniert es als Nachfolger der synthetischen Biologie (SynBio), mit besonderem Fokus auf die Produktion im industriellen Maßstab.
eXoZymes ist auf KI-entwickelte Enzyme spezialisiert, die außerhalb lebender Zellen in Bioreaktoren arbeiten und Rohstoffe in wertvolle Chemikalien, Arzneimittel und Biokraftstoffe umwandeln. Das Unternehmen hebt das Potenzial dieser Technologie hervor, traditionelle chemische Produktionsmethoden durch nachhaltige Alternativen zu ersetzen. Der Entwicklungsprozess, der durch KI und Enzyme unterstützt wird, verkürzt die Produktionszeiten erheblich, und das Unternehmen erwartet, in nur wenigen Wochen eine neue chemische Entwicklung bekannt zu geben.
- Introduction of innovative 'exozymes' technology potentially solving industrial scaling challenges in synthetic biology
- AI-powered development process significantly reduces chemical production timelines from months to weeks
- Technology enables sustainable production of valuable chemicals, medicines, and biofuels
- None.
Insights
The strategic rebranding to eXoZymes marks a pivotal evolution in the industrial biotechnology sector, introducing a potentially disruptive platform that bridges the critical gap between synthetic biology research and commercial-scale production. The company's AI-engineered enzyme technology addresses a fundamental challenge that has historically plagued the synthetic biology field - the ability to scale efficiently to industrial levels.
The platform's most compelling value proposition lies in its accelerated development cycle. Traditional chemical process development typically requires 6-18 months of R&D, while eXoZymes claims to reduce this to weeks. This 10-20x acceleration in development time could revolutionize the economics of specialty chemical and pharmaceutical production, particularly for:
- Custom pharmaceutical intermediates and APIs
- High-value specialty chemicals
- Sustainable biofuels
The decision to introduce 'exozymes' as an unprotected scientific term, rather than a trademarked brand, suggests confidence in their technology's potential to establish a new industry standard. This approach mirrors historical precedents where pioneering companies established new technological categories, such as CRISPR in gene editing.
The platform's cell-free nature offers several competitive advantages over traditional synthetic biology approaches:
- Reduced complexity in scaling processes
- Lower contamination risks
- More precise control over reaction conditions
- Potential for continuous production systems
However, the success of this rebranding and technological approach will ultimately depend on demonstrating consistent commercial-scale production capabilities and cost advantages over existing chemical synthesis methods. The upcoming announcement of their rapid-development chemical product will be a important proof point for validating their platform's capabilities.
- Rebranding Invizyne Technologies, Inc to eXoZymes Inc.
- Changing NASDAQ ticker from IZTC to EXOZ
- Introducing but not trademarking “exozymes” as a new scientific nomenclature
Monrovia, California, Feb. 12, 2025 (GLOBE NEWSWIRE) -- Today, Invizyne Technologies, Inc. - a pioneer of AI-engineered enzymes that can sustainably transform feedstock into essential chemicals, medicines, and biofuels, announced a corporate name change to eXoZymes, Inc. (“eXoZymes”) and that its common stock will begin trading on the Nasdaq Capital Market under the new ticker symbol of “EXOZ” effective before the market open.
No action is required by existing shareholders with respect to the name and ticker symbol change. The Committee on Uniform Securities Identification Procedures (CUSIP) also confirmed the CUSIP number assigned to the Company's common stock will remain unchanged.
“In response to feedback from our stakeholders and us having to continually explain which kind of ‘cell-free’ technology our platform falls under, we’re rebranding to both bring clarity around our core technology as well as set us apart from existing technologies. In fact, we believe that our technology is so fundamental and has so much potential that trying to label it with existing nomenclature falls short, which is why we’re introducing ‘exozymes’ as scientific concept,” states CEO of eXoZymes, Michael Heltzen. “We view exozymes as the logical successor to synthetic biology (SynBio), as they essentially represent the missing last step for most SynBio projects: Scaling on an industrial level, which is fundamental for economic success but mostly has eluded the SynBio space this far.”
“For the first time in history, we now have the tools and insight to control and optimize nature’s biological processes, enabling us to replace traditional chemical production methods with a sustainable and eco-friendly alternative: Exozymes. Exozymes are advanced enzymes engineered using AI to thrive in a bioreactor outside of living cells that now allow us to efficiently transform affordable and widely available feedstocks into a diverse range of valuable small-molecule chemicals, including active pharmaceutical ingredients, nutraceuticals, and biofuel,” said Tyler Korman, PhD, co-founder and VP of Research at eXoZymes. “As an example of how combining AI with enzymes speeds up the development process, relatively soon we anticipate announcing a new chemical that we took from idea to actual production in weeks. That short development cycle is a paradigm shift in itself.”
About eXoZymes Inc.
Founded in 2019, the company has developed a platform that - as a historic first - offers the tools and insight to control and optimize nature’s own biological processes, enabling their partners to replace traditional chemical production methods with a new sustainable and non-polluting alternative: Exozymes.
Exozymes are advanced enzymes engineered using AI to thrive in a bioreactor outside of living cells. Exozymes can replace toxic petrochemical processes and inefficient biochemical extraction with sustainable and scalable biosolutions to more efficiently transform biomass into essential chemicals, medicines, and biofuels.
By freeing enzyme-driven chemical reactions from the limitations imposed by cellular environments, exozyme biosolutions eliminate the scaling bottleneck that has hampered commercial success in the synthetic biology (SynBio) space, making exozymes the natural successor to most synthetic biology projects.
Inspired by insights from four recent Nobel Prizes in Chemistry, this technological platform ushers in the exozyme era - a paradigm shift in chemical production by introducing scalable and sustainable exozyme biosolutions.
While the company, eXoZymes Inc., has introduced “exozymes” (エキソザイム in Japanese katakana) as a scientific concept, they are not trademarking the concept, as they view it as a new nomenclature for wide adoption.
Learn more on exozymes.com.
Forward-Looking Statements
This press release contains "forward-looking statements." These forward-looking statements are made as of the date they were first issued and were based on current expectations, estimates, forecasts and projections as well as the beliefs and assumptions of management. Words such as “aim”, "expect," "anticipate," "should," "believe," "hope," "target," "project," "goals," "estimate," "potential," "predict," "may," "will," "might," "could," "intend," "shall" and variations of these terms or the negative of these terms and similar expressions are intended to identify these forward-looking statements.
Forward-looking statements are subject to a number of risks and uncertainties, many of which involve factors or circumstances that are beyond eXoZymes’ control. eXoZymes’ actual results could differ materially from those stated or implied in forward-looking statements due to a number of factors. The forward-looking statements included in this press release represent eXoZymes’ views as of the date of this press release. eXoZymes anticipates that subsequent events and developments will cause its views to change. eXoZyme’s undertakes no intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. These forward-looking statements should not be relied upon as representing eXoZymes’ views as of any date subsequent to the date of this press release.
Media contacts
Lasse Görlitz, VP of Communications
(858) 319-7135
press@exozymes.com
Investor Relations Contact:
IR@exozymes.com
FAQ
What is the new stock symbol for eXoZymes (formerly Invizyne) on Nasdaq?
How does eXoZymes' AI-engineered enzyme technology work?
What advantage does EXOZ's exozymes technology have over traditional synthetic biology?
How fast can EXOZ develop new chemicals using their AI-enzyme technology?
